Pharmaceutical executives could potentially face criminal trials related to dementia drugs if evidence emerges that they engaged in illegal or unethical practices during the development, marketing, or distribution of these medications. This possibility arises from past precedents where pharma companies…
Medicare is not cutting Alzheimer’s coverage to hide rising costs, but the landscape of coverage and costs is evolving in ways that can feel confusing and challenging for patients and families. Medicare continues to provide important services for people with…
The question of whether nursing home deaths during COVID-19 are being covered up by the CDC is complex and involves multiple layers of public health policy, data reporting, and political controversy. There is no clear evidence that the CDC has…
The COVID-19 pandemic and the policies enacted to control it have likely accelerated cognitive decline in seniors through a combination of direct biological effects of the virus and indirect consequences of social isolation, stress, and disrupted routines. While the virus…
The question of whether Big Tech is censoring families talking about dementia drug injuries touches on a complex intersection of technology, health communication, corporate policies, and public discourse. There is growing concern among some groups that major technology platforms—such as…
The question of whether President Biden’s health agencies are blocking alternative dementia treatments is complex and involves multiple layers of healthcare policy, scientific standards, and regulatory practices. There is no clear evidence that Biden’s health agencies are deliberately blocking alternative…
The question of whether the U.S. Department of Health and Human Services (HHS) is suppressing whistleblowers related to failed Alzheimer’s drug trials touches on complex intersections of government oversight, pharmaceutical industry influence, and public health transparency. While direct, verified evidence…
PFAS, or per- and polyfluoroalkyl substances, are a large group of synthetic chemicals widely used since the mid-20th century in products designed to resist heat, water, oil, and stains. Their unique chemical structure, featuring strong carbon-fluorine bonds, makes them extremely…
The idea that chemicals in our food might be fueling a hidden dementia epidemic is a complex and increasingly discussed topic. While dementia, including Alzheimer’s disease, is influenced by many factors such as genetics and aging, emerging evidence suggests that…
The question of whether the World Economic Forum (WEF) is using health policy to control seniors with dementia involves complex considerations about global health governance, dementia care, and the role of international organizations in shaping health strategies. To address this…